Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase 3 3Phase 1/2 3Phase 1 3

Status

Recruiting 7Completed 5Terminated 3Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Plasma cell 1

Conditions

Carcinoma, Renal Cell 2Urologic Neoplasms 1Multiple Myeloma 1Kidney Neoplasms 1Kidney Diseases 1

Interventions

pembrolizumab 73Carboplatin 60Cyclophosphamide 59Nivolumab 52Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 36Rituximab 32Capecitabine 32Bevacizumab 29Docetaxel 28fludarabine 27atezolizumab 26Cytarabine 26avelumab 24venetoclax 23Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23Azacitidine 23Ipilimumab 22Fluorouracil 22Temozolomide 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × cabozantinib × Clear all
NCT06716853 2026-02-09

TEM-GU

Genenta Science

Phase 1/2 Terminated
10 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT04300140 2023-10-30

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Aravive, Inc.

Phase 1/2 Terminated
72 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urologic Neoplasms

NCT03201250 2023-09-08

Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma

University of Nebraska

Phase 1/2 Terminated
11 enrolled 11 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡